Universal Beteiligungs und Servicegesellschaft mbH Raises Holdings in Hologic, Inc. $HOLX

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 12.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,848 shares of the medical equipment provider’s stock after acquiring an additional 35,667 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.14% of Hologic worth $21,587,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of HOLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Hologic by 10.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after purchasing an additional 3,520 shares in the last quarter. Empowered Funds LLC grew its position in Hologic by 27.7% during the first quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after buying an additional 3,790 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Hologic by 71.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 10,909 shares of the medical equipment provider’s stock valued at $707,000 after buying an additional 4,548 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Hologic by 38.3% in the second quarter. Farther Finance Advisors LLC now owns 2,538 shares of the medical equipment provider’s stock worth $165,000 after acquiring an additional 703 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Hologic by 129.4% in the second quarter. GAMMA Investing LLC now owns 7,269 shares of the medical equipment provider’s stock worth $474,000 after acquiring an additional 4,100 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $75.11 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.34. The firm has a market capitalization of $16.74 billion, a PE ratio of 30.29, a P/E/G ratio of 2.13 and a beta of 0.69. The business’s 50 day moving average price is $74.78 and its 200-day moving average price is $70.45.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the firm posted $1.01 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of analyst reports. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective on the stock. in a report on Friday, November 21st. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Mizuho lowered Hologic from an “outperform” rating to a “neutral” rating and increased their target price for the company from $70.00 to $78.00 in a research report on Thursday, October 23rd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $78.00 price target on shares of Hologic in a research note on Wednesday, October 22nd. Three analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $79.31.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.